Laura E Schanberg, Lily Yeruk Mulugeta, Bolanle Akinlade, Hermine I Brunner, Jianmeng Chen, Robert A Colbert, Vincent Delgaizo, Marc R Gastonguay, Rachel Glaser, Lisa Imundo, Daniel J Lovell, Jocelyn H Leu, Nael M Mostafa, Robert M Nelson, Peter A Nigrovic, Nikolay P Nikolov, Lisa G Rider, Rebecca Rothwell, Chandrahas Sahajwalla, Renu Singh, Vikram Sinha, Carolyn L Yancey, Lynne Yao
OBJECTIVE: Stakeholders met to address persistent challenges facing development of therapeutics for polyarticular JIA (pJIA), which result in fewer approved therapies for children with pJIA than adults with rheumatoid arthritis (RA) and long lag times from adult RA approval to pediatric labeling. Ensuring new medications are authorized in a timely manner to meet the needs of JIA patients worldwide is critically important to multiple stakeholders. METHODS: The FDA in collaboration with University of Maryland Center for Regulatory Science and Innovation (MCERSI) held a public workshop entitled "Accelerating Drug Development for polyarticular juvenile idiopathic arthritis (pJIA) on October 2, 2019, to address challenges surrounding access to new medications for children and adolescents with pJIA...
April 17, 2023: Arthritis & Rheumatology